GMP False Claims Case Falters, But Pharma Isn’t In Clear Yet
Executive Summary
First appellate court ruling on the role of good manufacturing practice violations in False Claims Act suits could make future cases tougher, but legal experts still predict a flurry of such suits, with other jurisdictions weighing in. And the Justice Department has its own opinion on the matter.
You may also be interested in...
Ranbaxy’s $500 Million Settlement Includes Criminal Penalties
The generic drug maker’s Ranbaxy USA Inc. subsidiary pleads guilty to seven felony counts brought in connection with a longstanding government investigation into data integrity issues and manufacturing violations at two Indian sites, but while the settlement eliminates some worries for the firm, operations still face the weight of a FDA consent decree.
GMP Violations At GSK's Former Puerto Rico Plant Are Basis Of $750 Million DoJ Settlement
In the first False Claims Act case alleging cGMP violations the government cites microbial contamination, split tablets and product mix-ups.
Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length
Recently retired US FDA Principal Deputy Commissioner Janet Woodcock will be advising the Haystack Project, with the goal of helping rare disease organizations encourage creativity in drug development programs without jeopardizing regulatory success, Woodcock told the Pink Sheet in an interview.